{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Entero Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"ENTO"},"Address":{"label":"Address","value":"777 YAMATO ROAD,SUITE 502, BOCA RATON, Florida, 33431, United States"},"Phone":{"label":"Phone","value":"+1 561 589-7020"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Entero Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. The Company is currently advancing a therapeutic development pipeline with multiple late-stage clinical programs built around its proprietary technologies, including: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for Celiac disease; capeserod, a selective 5-HT4 receptor partial agonist being developed for gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency."},"CompanyUrl":{"label":"Company Url","value":"https://www.enterothera.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"James E. Sapirstein","title":"Chairman & Chief Executive Officer"},{"name":"Jennifer A. Sealey-Voyksner","title":"Vice President-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}